EXAI
NASDAQExscientia Plc
Latest news
25 items- SECSEC Form 15-12G filed by Exscientia Plc15-12G - Exscientia plc (0001865408) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Exscientia PlcSC 13G/A - Exscientia plc (0001865408) (Subject)
- 13D/GAmendment: SEC Form SC 13D/A filed by Exscientia PlcSC 13D/A - Exscientia plc (0001865408) (Subject)
- SECSEC Form S-8 POS filed by Exscientia PlcS-8 POS - Exscientia plc (0001865408) (Filer)
- SECSEC Form S-8 POS filed by Exscientia PlcS-8 POS - Exscientia plc (0001865408) (Filer)
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- SECSEC Form 25-NSE filed by Exscientia Plc25-NSE - Exscientia plc (0001865408) (Subject)
- PRRecursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryRecursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, wi
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- PRRecursion and Exscientia Shareholders Approve the Proposed CombinationSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET / 5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- PRExscientia Achieves Milestones for Two Programmes in Sanofi CollaborationBoth programmes demonstrate Exscientia's ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages Exscientia plc (NASDAQ:EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- PRExscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet levels Identified PD biomarkers related to LSD1 inhibitor treatment Exscientia plc (NASDAQ:EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain. "As our precision-designed LSD1 and MALT1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes," said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. "These
- PRData Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual MeetingRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. ASBMR is being held September 27 – 30, 2024 in Toronto, Canada. "From my team's earlier work published in 2002 and 2005, we knew that ENPP1 could be a targetable molecule to modulate TNAP's all-important substrate PPi. I am delighted that we have now been able to de
- SECAmendment: SEC Form 6-K/A filed by Exscientia Plc6-K/A - Exscientia plc (0001865408) (Filer)
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- PRExscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceExscientia plc (NASDAQ:EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST). A live webcast of the fireside chat will be available on the Company's website, under the "Investors & Media" section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation. About Exscientia Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients,
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- PRExscientia Business Update for Second Quarter and First Half 2024Entered into definitive agreement to combine with Recursion to create a global technology-enabled drug discovery leader with end-to-end capabilities Acquired full rights to GTAEXS617 (CDK7 inhibitor), with initial Phase I monotherapy data expected in 2H24 Launched AWS AI-powered platform to advance drug discovery LSD1 and MALT1 inhibitor programmes continue to progress towards the clinic, on track for 2H24 IND/CTA submissions Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2024, are summarised below. "Last week, we announced that Exscientia entered into a
- SECSEC Form 6-K filed by Exscientia Plc6-K - Exscientia plc (0001865408) (Filer)
- PRRecursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End CapabilitiesBrings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone
- PRLatest Updates of Viva Biotech's Portfolio CompaniesHONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization. Recently, Viva Biotech's portfolio companies have new updates. Keep reading for more details. Nerio Therapeutics, A Viva Biotech's Portfolio Company, Was Successfully Acquired by Boehringer Ingelheim for $1.3 Billion San Diego, California - On July 29, 2024, Boehringer Ingelheim announced the addition of an innovative preclinical program with the acquisition of Nerio Therap
EXAI FAQ
7 questionsWhat does Exscientia Plc do?
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.Where does EXAI stock trade?
Exscientia Plc (EXAI) is listed on NASDAQ.What sector and industry is EXAI in?
Exscientia Plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Exscientia Plc go public?
Exscientia Plc (EXAI) completed its IPO in 2021.What are analysts saying about EXAI?
Exscientia Plc has had 2 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2024-07-09. Recent price targets cluster around $900.00.What companies are similar to EXAI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare EXAI side-by-side with any of them on Quantisnow.How can I track EXAI on Quantisnow?
Quantisnow aggregates Exscientia Plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EXAI to receive live email and push alerts on every new disclosure.